Table 1.
Impact of CYP2C9polymorphisms on pharmacokinetic parameters for single doses of piroxicam and tenoxicam in healthy Brazilian individuals.
| Drug/parameter | CYP2C9 genotypes | ANOVA P valuea | ||
|---|---|---|---|---|
| *1/*1 | *1/*2 | *1/*3 | ||
| TENOXICAM (20 Mg p.o.) | ||||
| Cmax (μg mL−1) | 2.7 ± 0.9 | 2.7 ± 0.6 | 2.6± 0.8 | 0.964 |
| AUCinf (μg mL−1h) | 190 ± 48 | 261 ± 14b | 335 ± 126b | 0.004 |
| CL/Fcor (mL h−1kg−1) | 1.8 ± 0.4 | 1.2 ± 0.1b | 1.1 ± 0.4b | 0.011 |
| PIROXICAM (20 Mg p.o.) | ||||
| Cmax (μ g mL−1) | 2.5 ± 0.7 | 2.2 ± 0.5 | 2.4 ± 0.4 | 0.44 |
| AUCinf (μ g mL−1h) | 154 ± 37 | 256 ± 97b | 259 ± 95b | 0.0001 |
| CL/Fcor (mL h−1 kg−1) | 2.0 ± 0.5 | 1.3 ± 0.4b | 1.3 ± 0.4b | 0.0001 |
Data are given as mean ±S.D. aANOVA performed on log-transformed values, for comparison across the three genotypes. bP < 0.05 for pair-wise comparisons between CYP2C9*1/*2 or CYP2C9*1/*3 versus CYP2C9*1/*1 (Student–Newman–Keuls test).